A subset of patients who present with acute respiratory symptoms go on to develop acute hypoxic respiratory failure with bilateral lung infiltrates. These patients fulfill clinical criteria for the acute respiratory distress syndrome (ARDS), including (1) acute onset, (2) Pa O2 :FI O2 ratio 200 mm Hg, (3) bilateral pulmonary infiltrates on chest radiographs, and (4) the absence of congestive heart failure, defined as pulmonary artery wedge pressure 18 mm Hg (when measured) or no clinical evidence of left atrial hypertension.
A subset of patients who present with acute respiratory symptoms go on to develop acute hypoxic respiratory failure with bilateral lung infiltrates. These patients fulfill clinical criteria for the acute respiratory distress syndrome (ARDS), including (1) acute onset, (2) Pa O2 :FI O2 ratio 200 mm Hg, (3) bilateral pulmonary infiltrates on chest radiographs, and (4) the absence of congestive heart failure, defined as pulmonary artery wedge pressure 18 mm Hg (when measured) or no clinical evidence of left atrial hypertension.
1 Defined in this way, the criteria for ARDS are purely clinical and do not require histological input. Although this definition has the virtue of ease of clinical application, it makes ARDS a "mixed bag" in terms of etiology and underlying pathology, rather than a well-defined clinicopathological entity. [2] [3] [4] [5] From an etiologic standpoint, ARDS occurs in a wide variety of wellknown settings, including infection/sepsis, shock, trauma, aspiration and oxygen toxicity, among many others 6 ; a few cases occur without an apparent cause or underlying context. With regard to underlying pathology, the most common histological finding in ARDS is diffuse alveolar damage (DAD). 2, 5, 7 However, other entities such as infectious pneumonias, culture-negative acute bronchopneumonia, capillaritis with alveolar hemorrhage, eosinophilic pneumonia, and organizing pneumonia are found to be the underlying pathology in a surprisingly high proportion of cases of ARDS. 2, 5 The challenge for the clinician managing patients with ARDS is to identify cases that have a treatable or potentially reversible cause, and distinguish them from those in whom the etiology is unknown and the response to therapy is likely to be poor. The existence of cases with the latter combination of dismal circumstances has been known since 1935, when Louis Hamman and Arnold Rich described four patients with acute respiratory failure of unknown etiology. All four patients died of respiratory failure and were found at autopsy to have a distinctive underlying pathology characterized by diffuse interstitial fibroblast proliferation-a finding that in
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► acute interstitial pneumonia ► acute lung injury ► acute respiratory distress syndrome ► diffuse alveolar damage modern times is recognized as the organizing stage of DAD. 8, 9 This acute idiopathic condition was subsequently given the eponym Hamman-Rich syndrome. Over the years, however, the term Hamman-Rich syndrome began to be incorrectly used as an all-inclusive expression for all forms of lung fibrosis, including chronic forms of pulmonary interstitial fibrosis. 10, 11 The term acute interstitial pneumonia (AIP) was introduced in 1986 by Katzenstein et al for cases identical to the Hamman-Rich syndrome to highlight the fact that the Hamman-Rich syndrome is an acute form of idiopathic interstitial lung disease, clinically and histologically distinct from chronic forms of idiopathic interstitial lung disease, the prototype of which is usual interstitial pneumonia (UIP)/ idiopathic pulmonary fibrosis (IPF).
12-14
This review clarifies the diagnostic criteria and terminology of AIP, discusses the etiologies that need to be excluded before a diagnosis of AIP can be made, highlights entities that should be considered in the differential diagnosis, and outlines the salient clinical and pathological features.
Definition (Diagnostic Criteria)
The key elements for a diagnosis of AIP are as follows 12,14-16 :
1. Acute onset of respiratory symptoms resulting in severe hypoxia and, in most cases, acute respiratory failure 2. Bilateral lung infiltrates on radiographs 3. The absence of an identifiable etiology or predisposing condition despite adequate clinical investigation (see later discussion) 4. Histological documentation of DAD The term AIP has the virtue of communicating the acute presentation and the prominent involvement of the pulmonary interstitium, which was the original intent of the term. In this way, the term AIP was an improvement over the eponym Hamman-Rich syndrome, which conveyed no useful information to the reader. However, although one source of confusion was eliminated (it is now clear that the HammanRich syndrome is an acute interstitial process), the term AIP does not mention the underlying pathology (DAD), or the requirement that known causes of DAD be excluded before making the diagnosis. The current terminology is confusing in that DAD due to known causes is simply referred to as DAD (stating the cause), whereas DAD of unknown cause is termed AIP, implying that the lack of an identifiable etiology defines a discrete entity. The reader will note obvious parallels to UIP, which is termed UIP (stating the cause) when it occurs in the context of a known etiology such as systemic sclerosis, whereas the term IPF is applied when UIP is of unknown etiology.
Some published articles have used the term AIP for any patient with acute respiratory failure and bilateral infiltrates on radiographs that are assumed to be "interstitial." Such cases of "AIP" do not meet the diagnostic criteria for AIP, in that either an underlying cause is present [17] [18] [19] or there is no histological documentation of DAD. 18, 19 The following discussion refers only to cases that meet the diagnostic criteria of AIP already enumerated here. ►Table 1 provides a summary of the published series of AIP.
9,12,20-29

Clinical Features
AIP can affect patients of any age and sex. Patients have ranged from 13 to 79 years of age. 12, 29 There is no gender predilection. The condition has been reported in pregnancy.
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Many (but not all) patients with AIP were previously healthy. The disease is often preceded by a viral-like or flulike prodromal illness or upper respiratory tract infection characterized by fatigue and myalgias, followed by acute onset of dyspnea and cough, accompanied in some patients by fever.
9,23,29
Fever may precede respiratory symptoms. 29 The acuteness of the onset of symptoms is a defining feature of AIP; the duration of symptoms in the original series ranged from 2 to 11 days. 
Radiology
The main radiological finding in DAD is the presence of bilateral lung infiltrates, which vary from patchy to diffuse and are often described as alveolar. The high-resolution computed tomographic (CT) findings of AIP have been well described. [20] [21] [22] 30 They include bilateral ground-glass opacities and/or bilateral airspace consolidation (opacification) (►Fig. 1). These findings can be seen in other diseases and are therefore nonspecific. Although traction bronchiectasis and honeycombing have been observed in some patients with putative AIP, 30 it is likely that these features indicate the presence of an underlying chronic interstitial fibrosing process such as UIP/IPF rather than pure DAD/AIP (see "Acute Exacerbation of IPF").
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Pathology of AIP-Diffuse Alveolar Damage
Because the histological finding of DAD is one of the key diagnostic criteria of AIP, a lung biopsy is required at some point during the clinical course; in patients who die without an antemortem biopsy, histological examination of the lungs at autopsy can confirm the diagnosis. In addition to hyaline membranes and proliferating interstitial fibroblasts, several other histological findings are variably present in DAD, many of which often distract practicing pathologists from the correct diagnosis. These include alveolar collapse/atelectasis, hyperplasia of type 2 pneumocytes (which may be marked), edema within the alveolar septa, thrombi within small pulmonary arteries, squamous Organisms are, by definition, absent. Cases in which organisms are apparent on biopsy should not be termed AIP; instead, they should be referred to simply as DAD, and the cause should be stated. The role of lung biopsy is not just limited to identifying DAD but also extends to identification of an underlying etiology. In a study of 58 cases of DAD diagnosed on surgical lung biopsies, the biopsy provided the etiology in six (10%), mainly by identifying underlying UIP (hence diagnosing acute exacerbation of IPF) or an infection such as cytomegalovirus (CMV). 28 In immunocompromised patients who at first glance appear to have DAD of unknown cause on histological examination, performing a Grocott's methenamine silver (GMS) stain for fungal organisms can be helpful given that Pneumocystis pneumonia can occasionally manifest histologically as DAD instead of the usual intraalveolar frothy material.
31,32
Etiology of DAD-What to Exclude before Diagnosing AIP
As already mentioned, DAD is the pathological basis of AIP. Because AIP is defined as an idiopathic entity, known causes of DAD need to be excluded before the term AIP is applied. In practice, the usual diagnostic sequence is that the finding of DAD on a lung biopsy prompts consideration of AIP, and it is at this point that exclusion of underlying occult etiologies becomes an issue. would exclude such patients because these cases have now been determined to be specific noninfectious, transplantrelated pulmonary complications and have been labeled idiopathic pneumonia syndrome, peri-engraftment respiratory distress syndrome, and diffuse alveolar hemorrhage syndrome.
23,57
Infection is the most important etiology to exclude in patients in whom a diagnosis of AIP is being considered clinically, or in whom DAD has been diagnosed on a lung biopsy. This should take the form of microbiological and serological testing, including cultures of sputum, blood, bronchial washings, and/or bronchoalveolar lavage (BAL) fluid. It is important to remember (for pulmonologists or surgeons performing lung biopsies) that a representative piece of biopsied lung tissue should be submitted for cultures. Histological examination can be the key diagnostic modality for detecting organisms that are impossible to culture (e.g., Pneumocystis), or detected late in cultures (such as many mycobacteria, Blastomyces and Histoplasma). These organisms are often easily and rapidly detected by histological examination of lung biopsy specimens. Pneumocystis pneumonia, in particular, should always be considered in the differential diagnosis of an AIP-like clinical presentation in immunocompromised patients because Pneumocystis can cause DAD histologically 31, 32 and manifest as ARDS clinically. 2 Pneumocystis organisms may be difficult or impossible to detect by modalities other than histological examination. CMV can also be identified as a cause of DAD by histological examination, either by identification of the pathognomonic inclusions on routine hematoxylin and eosin (H&E)-stained sections or by immunohistochemistry.
28,37
Connective tissue diseases (collagen vascular diseases) are another major group of diseases that may manifest pathologically as DAD. 58 The main connective tissue diseases that are associated with DAD are dermatomyositis/polymyositis (including the antisynthetase syndrome), systemic sclerosis (scleroderma), systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, and mixed connective tissue disease (►Table 2). DAD usually occurs in patients with established disease, and is discovered either at presentation along with other systemic features, or later in the course of the illness. However, it can occasionally be the presenting manifestation of the disease. 43, 46 Therefore, the histological finding of DAD on lung biopsy in a patient without an apparent underlying etiology should always prompt a workup for connective tissue disease. The required serological tests to perform and the interpretation of the results in the context of these lung-dominant undifferentiated connective tissue diseases is still a moving target; the issues surrounding this problem have been well summarized by Fischer and colleagues.
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DAD is the most commonly reported histological manifestation of drug toxicity. 52 Many drugs can cause DAD, the most classic being chemotherapeutic agents such as bleomycin and busulfan. Of the nonchemotherapeutic agents, amiodarone and nitrofurantoin are perhaps some of the best-known causes. Drug-related lung disease is always a complicated diagnosis that is difficult if not impossible to prove. In most cases, a presumptive diagnosis of drug toxicity is based on onset of disease after commencement of drug therapy, amelioration of symptoms with cessation of therapy, and exclusion of other causes, the most important being infection. Although lung biopsies help to exclude infection and pinpoint the underlying pathological manifestation (including DAD), it is important to stress that no specific pathological findings are unique to drug-related lung disease, or pathognomonic of any specific drug. Despite the difficulty in implicating a drug with certainty, the occurrence of DAD in the context of therapy with a drug known to be associated with DAD should exclude a diagnosis of AIP.
Pathogenesis
DAD (and thus AIP) is a manifestation of acute lung injury.
Regardless of the type of injurious agent, the injury typically damages alveolar epithelium as well as alveolar septal capillary endothelium. Histologically, injury to these two elements (epithelium and endothelium) results in a mixture of debris derived from necrotic epithelial cells and serum proteins derived from the injured capillaries that forms hyaline membranes. The subsequent repair reaction, termed the organizing, proliferative, or fibroproliferative stage of DAD, is characterized by incorporation of hyaline membranes into the interstitium accompanied by marked proliferation of fibroblasts within the interstitium. The assertion that the fibroblasts are indeed proliferating rapidly is supported by multiple techniques, including incorporation of tritiated thymidine, and a high Ki-67 labeling index by immunohistochemistry. 12, 59 The presence of histologically diffuse fibroblast proliferation separates organizing DAD (AIP) from UIP, in which most of the fibrosis is chronologically "older" (manifested mainly by collagen deposition), with only tiny foci of fibroblast proliferation.
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Differential Diagnosis
The differential diagnosis of AIP includes infection, congestive heart failure, ARDS, acute exacerbation of IPF, and DAD due to known causes.
Infection
As already mentioned, the clinical and radiological features of fulminant infections can be identical to those of AIP. Therefore, every attempt should be made to identify an organism before a label of AIP is applied. Clinicians should request appropriate microbiological and serological tests, and pathologists should examine biopsy specimens for organisms. If the patient is immunocompromised, it is vital that this information be provided to the pathologist because this increases the intensity of the search for an organism and may trigger the use of special histochemical or immunohistochemical stains. Polymyositis/dermatomyositis 24, 25, 28, 43, 45, 46 Systemic lupus erythematosus 25 Systemic sclerosis (scleroderma) 28, 43, 47 Mixed connective tissue disease 28, 43 Sjögren syndrome Congestive Heart Failure Congestive heart failure (CHF) often enters the differential diagnosis of patients eventually shown to have AIP. Exclusion of CHF is a key criterion in the definition of ARDS, and the same applies to AIP. Radiologically, ARDS and AIP can be indistinguishable from cardiogenic pulmonary edema. 4 In fact, ARDS and AIP are often referred to as noncardiogenic pulmonary edema, a somewhat misleading term given that the pathology in these cases is DAD rather than edema. Today, the diagnosis of CHF can be made reliably with the use of various noninvasive tools such as echocardiography and serum B-type natriuretic peptide (BNP) levels. In unclear cases the use of Swan-Ganz catheterization to obtain pulmonary capillary wedge pressure helps to establish the diagnosis.
ARDS
There are so many common features between ARDS and AIPacute onset of symptoms, severe hypoxia, bilateral infiltrates on radiographs, respiratory failure requiring mechanical ventilation, poor prognosis, high fatality rate, and DAD on histology-that the reader may well wonder why ARDS and AIP are not the same entity! 3,11,60 In fact, AIP has occasionally been labeled idiopathic ARDS. Comparison of the diagnostic criteria for ARDS and AIP reveals that the definitions are nearly identical, with two key differences. First, ARDS is defined solely by clinical criteria, whereas the criteria for AIP require both clinical and pathological input, thus mandating histological examination of the lung for diagnosis. This makes AIP a somewhat more narrowly defined entity, whereas ARDS, being diagnosed on clinical grounds, is more heterogeneous in terms of underlying pathology. 2,61 For example, in some cases that meet the clinical definition of ARDS, histological examination reveals not DAD but other findings such as infectious pneumonia, capillaritis with alveolar hemorrhage, or organizing pneumonia. Second, the definition of AIP requires that the disorder be of unknown etiology, whereas the definition of ARDS holds true regardless of whether an underlying cause is identified. With these definitions in mind, therefore, ARDS and AIP should be conceptualized not as two distinct entities or diseases, but as differing ways of defining subsets of patients with severe acute lung injury. Because the definitions overlap, both diagnoses can often be applied to the same patient. Thus some patients with ARDS fulfill the clinical and histological criteria for AIP, and virtually all patients with AIP meet the clinical diagnostic criteria for ARDS. 9, 11, 14 The relationship between ARDS and AIP is illustrated schematically in ►Fig. 3.
The presence of multiorgan failure in ARDS and its absence in AIP has been cited as a difference between the two entities.
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Although multiorgan failure is more common in ARDS than in AIP, 24 there are no published data to show that multiorgan failure is an accurate discriminator between these conditions.
Acute Exacerbation of IPF
The preceding discussion may lead the reader to think that interstitial fibrosis can always be neatly categorized into acute and chronic forms. However, there is a group of patients with chronic interstitial fibrosis (either established or occult) who develop superimposed acute lung injury (which may also involve fibrosis), thus developing a mixed acute-onchronic fibrosing picture. The classic example is patients with known UIP/IPF who develop superimposed DAD, often of unknown cause. [62] [63] [64] [65] Although the resultant acute idiopathic illness is similar to AIP, the key difference is in the presence of underlying chronic fibrosis. Therefore, the appropriate term for this condition is not AIP but acute exacerbation of IPF. 64, 66 The existence of such acute-on-chronic cases explains why it has been so difficult in the past to neatly separate acute forms of pulmonary fibrosis (such as AIP) from chronic forms such as UIP/IPF. Some of these patients already have a known underlying occult chronic interstitial lung disease (e.g., IPF) when the acute injury supervenes, whereas in others the superimposed acute lung injury is the first manifestation of lung disease, and the underlying chronic interstitial fibrosis is discovered only when the superimposed acute lung injury brings the patient to clinical attention. Evidence of a mixture of chronic and acute processes is often difficult to demonstrate but can be sought in several ways. Clinically, a patient with known chronic pulmonary fibrosis may suddenly deteriorate and develop acute respiratory failure. Radiologically, there may be evidence of chronic interstitial fibrosis (honeycombing and traction bronchiectasis/brochiolectasis) 66 as well as acute interstitial fibrosis (ground-glass opacities or consolidation). Finally, histology, which is the gold standard in evaluating such cases, may show a combination of acute and chronic processes such as DAD and UIP in the same biopsy. 9, 65 It is likely that reports of traction bronchiectasis and honeycombing (features typically seen in UIP) in purported cases of AIP represent occult underlying UIP rather than pure AIP. 21 In fact, traction bronchiectasis and honeycomb change have been claimed to be adverse prognostic features in AIP, an observation which (in hindsight) suggests that these patients had underlying UIP, which may be a better explanation for their worse prognosis than if they had AIP alone.
DAD Due to Known Causes
DAD caused by known etiologies is clinically and radiologically identical to AIP, the only difference being one of terminology. As discussed in the prior sections, known causes of DAD need to be excluded clinically before the term AIP is used.
Treatment
There is no proven effective therapy for AIP. rates. 24, 27 In the series reported by Quefatieh et al, only one of eight patients died. The reasons for this strikingly low mortality are unclear, although the authors claimed that early and more frequent corticosteroid therapy in their patients may have been responsible. In Suh et al's series, eight of 10 patients survived to discharge. The authors claimed that their lower mortality may have been achieved by a combination of early lung biopsy, pulse high-dose corticosteroids, and a lungprotective strategy during mechanical ventilation. Most series of AIP have not been able to replicate these findings, the mortality in the majority of these ranging from 50 to 100% 9, 20, 21, 26, 28, 29 despite the use of intravenous high-dose corticosteroids 9,26,28,29 and lung-protective ventilation strategies.
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In one study of DAD, the hospital mortality rate from AIP (50%) was similar to that from DAD due to known causes (53%), suggesting that in patients who have DAD as their underlying pathology, identification of an underlying etiology does not necessarily improve the outcome. 28 In fact, to date, no consistent clinical or pathological features identify those patients with DAD who are likely to have a better outcome.
9,61
Long-term survival is possible after recovery from AIP, with documented survival for up to 2 to 4 years after diagnosis.
9,23 Progression of AIP to chronic interstitial lung disease and honeycomb change has been reported, which seems to imply that AIP can evolve into UIP. 23 However, an alternative explanation for this observation is that the apparent episode of "AIP" was actually an acute exacerbation of underlying occult IPF, which may not have been detected at the time of the initial acute injury. Subsequently, the underlying chronic fibrosis may have become manifest over a period of time, at which time honeycombing became apparent.
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Summary
1. The defining features of AIP are rapid onset of respiratory symptoms, development of acute respiratory failure with bilateral lung infiltrates on radiographs, absence of an identifiable cause or predisposing illness despite adequate microbiological and serological studies, and documentation of DAD on histology (antemortem by surgical lung biopsy or postmortem at autopsy). The condition overlaps with ARDS, although it is defined differently (i.e., requires histological diagnosis of DAD and exclusion of known causes). 2. Almost all patients with AIP require mechanical ventilation. Most are treated with high-dose intravenous corticosteroids. Response to therapy is variable and usually poor. The mortality is greater than 50% in most series. However, a subset of patients survives to discharge. 3. DAD is characterized histologically by hyaline membranes in the early (acute) stage and interstitial fibroblast proliferation in later (organizing) stages. DAD is a purely pathological diagnosis, but AIP is not. By definition, AIP cannot be diagnosed by pathologists without knowledge of the clinical setting (acute respiratory failure, bilateral infiltrates, absence of etiology). 4. In the presence of radiological or pathological evidence of underlying UIP/IPF, the combination of acute respiratory failure and DAD should be termed acute exacerbation of IPF rather than AIP, even if the etiology is unknown, as is frequently the case. Patients with acute exacerbation of IPF -like those with AIP-have a poor prognosis, with the additional complication of underlying irreversible chronic pulmonary fibrosis.
